# Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

> **NCT06374459** · PHASE1,PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 152 (estimated)

## Conditions studied

- Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

## Interventions

- **DRUG:** Zumsemetinib
- **DRUG:** Capecitabine
- **DRUG:** Zoledronic acid
- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT06374459
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-30
- **Primary completion:** 2032-05-31
- **Final completion:** 2032-05-31
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06374459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06374459, "Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06374459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*